User profiles for Michael Doukas
Doukas Michaelmosaiic GmbH Verified email at mosaiic.com Cited by 2241 |
[HTML][HTML] Simulation in manufacturing: Review and challenges
D Mourtzis, M Doukas, D Bernidaki - Procedia Cirp, 2014 - Elsevier
Simulation comprises an indispensable set of technological tools and methods for the
successful implementation of digital manufacturing, since it allows for the experimentation and …
successful implementation of digital manufacturing, since it allows for the experimentation and …
Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study
…, EW Steyerberg, JJB van Lanschot, M Doukas… - The Lancet …, 2018 - thelancet.com
Background After neoadjuvant chemoradiotherapy for oesophageal cancer, roughly half of
the patients with squamous cell carcinoma and a quarter of those with adenocarcinoma have …
the patients with squamous cell carcinoma and a quarter of those with adenocarcinoma have …
[HTML][HTML] Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial
…, JJ Boonstra, PPLO Coene, JWT Dekker, M Doukas… - Bmc Cancer, 2018 - Springer
Background Neoadjuvant chemoradiotherapy (nCRT) plus surgery is a standard treatment
for locally advanced oesophageal cancer. With this treatment, 29% of patients have a …
for locally advanced oesophageal cancer. With this treatment, 29% of patients have a …
Loss of LMOD1 impairs smooth muscle cytocontractility and causes megacystis microcolon intestinal hypoperistalsis syndrome in humans and mice
…, Y Han, V Nanda, Q Lyu, M Doukas… - Proceedings of the …, 2017 - National Acad Sciences
Megacystis microcolon intestinal hypoperistalsis syndrome (MMIHS) is a congenital visceral
myopathy characterized by severe dilation of the urinary bladder and defective intestinal …
myopathy characterized by severe dilation of the urinary bladder and defective intestinal …
[HTML][HTML] Design and planning of manufacturing networks for mass customisation and personalisation: challenges and outlook
D Mourtzis, M Doukas - Procedia Cirp, 2014 - Elsevier
Manufacturers and service providers are called to design, plan and operate globalized
manufacturing networks, addressing to challenges such as ever-decreasing lifecycles and …
manufacturing networks, addressing to challenges such as ever-decreasing lifecycles and …
[HTML][HTML] Potentiation of peptide receptor radionuclide therapy by the PARP inhibitor olaparib
…, CEMT Beerens, M Suker, M Doukas… - Theranostics, 2016 - ncbi.nlm.nih.gov
Metastases expressing tumor-specific receptors can be targeted and treated by binding of
radiolabeled peptides (peptide receptor radionuclide therapy or PRRT). For example, patients …
radiolabeled peptides (peptide receptor radionuclide therapy or PRRT). For example, patients …
Surveillance of premalignant gastric lesions: a multicentre prospective cohort study from low incidence regions
…, MP Peppelenbosch, W Lesterhuis, M Doukas… - Gut, 2019 - gut.bmj.com
Objective International guidelines recommend endoscopic surveillance of premalignant
gastric lesions. However, the diagnostic yield and preventive effect require further study. We …
gastric lesions. However, the diagnostic yield and preventive effect require further study. We …
The evolution of manufacturing systems: From craftsmanship to the era of customisation
D Mourtzis, M Doukas - Handbook of research on design and …, 2014 - igi-global.com
The transition from local economies to the global competitive landscape and the current
fluctuating customer demands drives a never-ending transformation of manufacturing systems. …
fluctuating customer demands drives a never-ending transformation of manufacturing systems. …
Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects
…, EB Anderson, MA Halepota, MA Doukas… - Investigational new …, 2005 - Springer
GW572016 is a dual EGFR-ErbB2 inhibitor that has promise as an anticancer agent. Two
phase I studies were conducted to determine the safety, tolerability and pharmacokinetics of …
phase I studies were conducted to determine the safety, tolerability and pharmacokinetics of …
Degassing of CO2, SO2, and H2S associated with the 2009 eruption of Redoubt Volcano, Alaska
The 2009 eruption of Redoubt Volcano, Alaska was particularly well monitored for volcanic
gas emissions. We report 35 airborne measurements of CO 2 , SO 2 , and H 2 S emission …
gas emissions. We report 35 airborne measurements of CO 2 , SO 2 , and H 2 S emission …